Monte Rosa Therapeutics, Inc. (GLUE) reported Q3 Revenue
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts GLUE Hot Sheet
Join SI Premium – FREE
Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE) reported Q3 Revenue for the quarter came in at $12.77 million versus the consensus estimate of $7.77 million.
For earnings history and earnings-related data on Monte Rosa Therapeutics, Inc. (GLUE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Indusind Bank Ltd (IIB:IN) PT Lowered to INR875 at Axis Capital Limited
- Coforge Ltd (COFORGE:IN) PT Raised to INR2,550 at Nuvama
- Tata Motors (TMCV:IN) PT Raised to INR645 at UBS
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
